Moderna Inc. once again emerged the winner in a court skirmish over claims that its COVID-19 vaccine infringed two Alnylam Pharmaceuticals Inc. patents. The U.S. Court of Appeals for the Federal Circuit issued a precedential opinion May 4, agreeing with a federal district court in Delaware that Moderna didn’t infringe the patents. For both courts, the decision was based on a single issue of claim construction.
Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following Bruton's tyrosine kinase inhibitors, the company reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 conference.
It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic, surpassed expectations with impressive safety, pharmacokinetic and biomarker data from a phase I trial, while potential fast-followers from Nurix Therapeutics Inc. and Recludix Pharma Inc. advanced via respective partnerships with Sanofi SA.
The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its members to speak on the record, as it ramps up the campaign against paying back over 23% on sales of branded drugs.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, GSK, Immunitybio, Kura, Kyowa Kirin, Mabwell, Moderna, Zealand.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bluebird, Checkpoint, Eli Lilly, Fortress, Grünenthal, Nurix, Sanofi, Simris.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actuate, In8bio, Kalvista, Kymera, Lyra, Nervgen, Novartis, Opus Genetics, Pharvaris, Regeneron, Replimune, Reviva, Teva, Viatris, Vera, Verastem, Xilio.
New hires and promotions in the biopharma industry, including: Aravax, Catalyst, Curogen, Fate, Instil Bio, Latus Bio, Scholar Rock, Seismic, Stratus, Sutro, Tela Bio, Vectory.
RSS
